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Background
Antiretroviral adherence issues are essential for success-
ful and sustained efficacy, and viral resistance
prevention.
Methods
One exceptional case regards an ex-IVDA patient (p)
with HIV infection known since 1985. Due to a severe
HIV-related immunosuppression (CD4: 37 cells/μL), in
1997 3TC, d4T, and indinavir was effectively started,
achieving after 3 months undetectable viremia and a
CD4 count of 315 cells/μL, but recurring urolithiasis
recommended a therapeutic shift. Since April 1997,3TC,
d4T, and ritonavir were suggested for 5 years, followed
by 3TC, d4T, and lopinavir-ritonavir (10 months), and
3TC, AZT, and lopinavir-ritonavir (6 years). However,
all proposed regimens were voluntarily taken by our p
(whose body weight was 75-80 Kg) at half-dose, as a sin-
gle daily dosage, against any recommendation, although
our p always maintained his “adherence” to his self-
made regimen, as assessed by monthly visits, direct drug
distribution-accountabilty, and adherence question-
naires. Surprisingly, viremia remained for 12 years at
non-detectable values (save one single detection of 1,260
HIV-RNA copies/μL), so that a genotypic resistance
testing was never feasible, while CD4 count ranged from
a nadir of 382 cells/μL (year 2001), to 525-794 cells/μL
since 2003.
Results
A second male p with a body weight of 69-73 Kg, since
2002 took all combined antiretroviral therapy at half
dosage (3TC 150 mg/day, AZT 300 mg/day, and lopi-
navir-ritonavir 2 cp/day for 7 years, as a single daily
dose), without showing detectable viremias, and CD4
counts >500 cells/μL. A third 48-y-old male, after two
changes of antiretroviral regimens due to dysmetabo-
lism, started the fixed dose AZT-3TC-abacavir combi-
nation at half dosage (one pill/day), and since 2003
had a persistingly negative viremia, and a CD4 count
always >650 cells/μL. In both these last 2 p, genotypic
resistance testing was not feasible (undetectable
viremia).
Discussion
Although recognizing the limitation of anecdotal obser-
vations, and our impossibility to resort to resistance
testing and therapeutic drug monitoring, however the
long-term maintenance of an excellent virologic-immu-
nological situation in 3 p with an adherence voluntarily
limited to 50% of recommended dosages depite all
counselling, deserves discussion. A 50% compliance is
considered absolutely inadequate in HIV disease treat-
ment. Anyway, all our 3 p are somewhat “adherent” to
their 50% dosage regimens, and are re-enforced in their
wrong consideration by checking every 3 months their
excellent clinical-laboratory situation, and by their long-
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term, unchanged therapy response. Health care profes-
sionals are embarrassed in discussing this inappropriate
mode of antiretroviral seld-administration, but lack of
supporting elements to opposite to the strongloy radi-
cated p’s thoughts.
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